Enzalutamide in Patients With Castration-Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient Program-Reference-Cited by-同舟云学术

Enzalutamide in Patients With Castration-Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient Program

Published:2017-06 Issue:3 Volume:15 Page:e315-e323
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Papazoglou Dimitrios,Wannesson Luciano,Berthold Dominik,Cathomas Richard,Gillessen Silke,Rothermundt Christian,Hasler Loretta,Winterhalder Ralph,Barth Andreas,Mingrone Walter,Nussbaum Catrina Uhlmann,von Rohr Lukas,von Burg Philippe,Schmid Mathias,Richner Jürg,Baumann Sylvia,Kühne Reto,Stenner Frank,Rothschild Sacha I.

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference26 articles.

1. Cancer statistics, 2015;Siegel;CA Cancer J Clin,2015

2. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer;Heidenreich;Eur Urol,2014

3. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

4. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial;de Bono;Lancet,2010

5. Abiraterone and increased survival in metastatic prostate cancer;de Bono;N Engl J Med,2011

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Can 68Ga-PSMA PET/CT-derived prostate-specific membrane antigen expression parameters predict prostate-specific antigen response to enzalutamide treatment?;Nuclear Medicine Communications;2021-05-06

2. Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review;Cancer Cell International;2020-08-26

3. Corticosteroids alleviate adverse events associated with enzalutamide in patients with metastatic castration‑resistant prostate cancer;Molecular and Clinical Oncology;2020-03-05

4. Initiation of Systemic Therapy During the Last 30 Days of Life in Patients With Metastatic Castration-resistant Prostate Cancer;Anticancer Research;2018-12-27

5. Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program;Future Oncology;2018-11